ALK and non-small cell lung carcinoma: Immunotherapy targeting programmed cell death receptor 1/ligand 1 (PD‐1/PD‐L1) has been shown to exhibit good effect and durable response in epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild‐type non‐small cell lung cancer (NSCLC) patients.1, 2, 3, 4, 5, 6, 7